NewsBenzingaNovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia Benzinga 2026.10.20 11:03 (GMT+0) Open on Benzinga Other news Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report How To Earn $500 A Month From Target Stock Ahead Of Q3 Earnings Stifel Reinstates Buy on Walmart, Announces $145 Price Target HC Wainwright & Co. Reiterates Buy on Perpetua Resources, Maintains $43.5 Price Target Midera Food Processing Q3 EPS $0.46 Misses $0.52 Estimate, Sales $229.000M Beat $219.940M Estimate Stifel Reinstates Hold on Target, Announces $155 Price Target
Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report